Curated News
By: NewsRamp Editorial Staff
October 27, 2026
Creative Biolabs Launches OMV & Exosome-Boosted CAR-T Platform
TLDR
- Creative Biolabs' dual OMV and exosome platform gives researchers a first-mover advantage in solid tumor CAR-T by addressing stroma and persistence simultaneously.
- The platform integrates OMV engineering for stroma remodeling and exosome engineering for CAR-T persistence, with customizable cargo loading for multimodal synergy.
- This platform could lead to more effective CAR-T therapies for solid tumors, offering hope to patients who currently lack viable treatment options.
- Engineered OMVs can transiently program tumor cells to display synthetic antigens, enabling universal CAR-T targeting across heterogeneous tumors.
Impact - Why it Matters
This launch matters because solid tumors remain the most formidable frontier in CAR-T immunotherapy, and single-vesicle approaches have typically addressed only one barrier at a time. By combining OMV and exosome engineering into a single customizable platform, Creative Biolabs is giving researchers a dual-mechanism toolkit to investigate stroma remodeling, metabolic persistence, and antigen escape in parallel. The inclusion of detoxified LPS strains and cell-free CAR-exosome options also reflects a growing emphasis on preclinical safety and translational feasibility. For the immuno-oncology field, this integrated approach could accelerate the evaluation of combination strategies and help move CAR-T therapies closer to meaningful activity in solid tumors, where patients currently have limited options.
Summary
Creative Biolabs, a global leader in biotechnology and contract research services, has launched an integrated OMV & exosome-boosted CAR-T development platform, a next-generation vesicle-engineering approach designed to help researchers investigate strategies for overcoming barriers to CAR-T activity in solid-tumor models. The announcement, made from Shirley, NY, highlights the company’s focus on addressing the persistent challenges that have limited CAR-T therapy’s effectiveness against solid tumors, including poor T-cell infiltration through dense tumor stroma, an immunosuppressive tumor microenvironment that drives metabolic exhaustion, safety concerns such as cytokine release syndrome, and antigen heterogeneity and escape.
The new platform integrates two complementary nanoscale vesicle technologies—bacterial outer membrane vesicles (OMVs) and mammalian-derived exosomes—into a unified, customizable pipeline. The OMV engineering arm functionally remodels the tumor microenvironment to promote CAR-T infiltration, and includes the BROAD-CAR system, in which OMVs transiently program tumor cells in vivo to display synthetic antigens recognized by a universal CAR-T construct. The exosome engineering arm provides a biocompatible support system to sustain CAR-T activity within the suppressive TME, with CAR-exosomes delivering antigen-specific tumor killing without live cell administration and selected systems being investigated for transport across biological barriers. A third service line equips both vesicle types with customized therapeutic payloads, including small molecules, nucleic acids, and proteins, for multimodal synergy and metabolic TME remodeling.
Creative Biolabs emphasizes that the platform offers several differentiators, such as antigen-independent targeting via synthetic marker installation, cell-free CAR-exosome options for preclinical repeat-dosing studies, and full technical validation including NTA sizing, high-resolution imaging, and pharmacokinetic profiling. The company also outlines practical criteria for researchers selecting a vesicle-engineering partner, including dual-modality integration, LPS detoxification data, and cargo co-loading capacity. For more information, researchers can visit https://www.creative-biolabs.com/car-t/ to download the full technical brief or contact the scientific team.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, Creative Biolabs Launches OMV & Exosome-Boosted CAR-T Platform
